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Atherosclerosis which results from gradual deposition of lipids in medium and large arteries is a leading cause of mortality
worldwide. Terminalia arjuna is a herb of Combretaceae family which contains hypolipidemic compounds and ﬂavonoids with
high antioxidative properties. This study was conducted to determine the eﬀe c to fe t h a n o l i cf r a c t i o no fT. arjuna on blood lipids
and atherosclerosis in rabbits fed with high fat diet (HFD). Twenty New Zealand rabbits of either sex were randomly divided
into ﬁve groups: the ﬁrst two were normal diet group and HFD (21% fat) group and the remaining three groups received
high cholesterol diet supplemented with standard drug (Atorvastatin 10mgkg−1 body weight), T. arjuna ethanolic fraction
(100 and 200mgkg−1 body weight), respectively. The concentration of total cholesterol (TC), low density lipoprotein (LDL)
cholesterol, triglycerides (TGs), very low density lipoprotein (VLDL) cholesterol and high density lipoprotein (HDL) cholesterol
was determined in rabbits at the start of the experiment, at the 14th, 30th days and at the end of the study. Anti-atherogenic index
wascalculatedfromthelipidproﬁleoftherabbitsbeforesacriﬁce.Attheendoftheexperimentalperiod,theaortawasremovedfor
assessmentofatheroscleroticplaques.Resultsshowthat T.arjunasigniﬁcantlydecreasesTC,LDLandTGlevels andincreasesHDL
and lessens atherosclerotic lesion in aorta (P < .05). Hence T. arjuna extract can eﬀectively prevent the progress of atherosclerosis.
This is likely due to the eﬀect of T. arjuna on serum lipoproteins and its antioxidant and anti-inﬂammatory properties.
1.Introduction
Atherosclerosis leading to coronary artery disease has
assumed a virulent disease ratio and is the principal cause
the world over in the developed as well as in the develop-
ing countries. Epidemiologic studies have demonstrated a
positive signiﬁcant relationship between plasma cholesterol
concentrations and coronary artery disease [1]. Clinical
manifestations are plaque formation in the artery walls. In
many cases, plaques protrude into the lumen of the artery
and if suﬃciently large, compromise the ﬂow of blood
[2]. Synthetic anti-hyperlipidaemic drugs like statins and
synthetic antioxidants like probucol are widely used to treat
atherosclerosis. Unfortunately, these drugs have side eﬀects
[3]. Hence, for treatment of atherosclerosis, much attention
has been focused on the use of natural products that have
very few side eﬀects [4]. One such plant is Terminalia arjuna
(Family: Combretaceae), used in traditional medicine for
treating ulcers [5], wound healing [6], and also for antibac-
terial [7], antimutagenic/anticarcinogenic [8, 9], antioxi-
dant and hypocholesterolemic activities [10]. The active
constituents of Terminalia include tannins, triterpenoid
saponins (arjunolic acid, arjunic acid, arjungenin, arjungly-
cosides), ﬂavonoids (arjunone, arjunolone, luteolin), gallic
acid, oligomeric proanthocyanidins (OPCs), polyphenols,
calcium, magnesium, zinc and copper [11]. Prolonged
administration of T. arjuna did not show any adverse eﬀect
on renal, hepatic and hematological parameters [12]. But
the fraction type of T. arjuna bark having a high degree
of antioxidant, anti-hyperlipidaemic and anti-atherogenic2 Evidence-Based Complementary and Alternative Medicine
activity is not well known. The eﬃcacy of T. arjuna fractions
as antidyslipidemic and antioxidant agents was found as:
ethanolic fraction > diethyl ether fraction > Petroleum
fraction (Saravanan et al., unpublished data). Therefore, the
present study has been undertaken to evaluate the anti-
atherogenic activity of ethanolic fractions of T. arjuna bark
powder in high fat diet (HFD) fed rabbits.
2. Methods
2.1. Plant Materials. T. arjuna supercritical extract was pro-
cured from Elles Pvt. Ltd, Chennai, India, and authenticated
by the Department of Botany at the Centre for Advanced
Research, Indian System of Medicine (CARISM), SASTRA
University,Thanjavur,India.Avoucherspecimen(No.0066)
has been deposited in the same department.
2.2. Fractionation of T. arjuna . Partial partition method
was adapted to fractionate the T. arjuna bark powder. In
total, 1500g of supercritical bark powder was soaked in
Petroleum ether for 7 days to defatting. On the 8th day, the
petroleum ether soluble matters were decanted and concen-
trated under the reduced pressure. Subsequently, every 7th
day consecutively, the fractionation was done similarly with
diﬀerent solvents from diethyl ether (TA-01), ethyl acetate
(TA-02) and ethanol (TA-03) in the same extract powder
as described by Row et al. [13]. All the fractions were dried
under reduced pressure and the brown color precipitate was
separated out. Fingerprinting of all fractions (TA-01, TA-
02 and TA-03) was done by HPTLC-based method (data
not shown). HPTLC ﬁngerprinting of these fractions of TA
were carried out using Linomet V spotter and scanned on
TLC scanner-II (CAMAG with Cats 3.18 software) using
silica gel 60 F254 TLC plates (Merck). The solvent system
used was chloroform:methanol (9:1) and toluene:ethyl
acetate:methanol:formicacid(5:4:1:0.5)andtheplatewas
scanned at 366nm. The peaks of three fractions observed
were compared with each other. Further, the fractions were
screened with GC-MS analysis and matched with Wiley &
NIST system Library (Perkin Elmer:Clarus 500).
2.3. Phytochemical Screening. Phytochemical screening was
performed on fractions TA-01, TA-02 and TA-03 to test
the presence of phenolics compounds, tannins, glycosides,
saponins, alkaloids and ﬂavonoids in the bark of T. arjuna
using appropriate tests [14].
2.4. Animals and Diet. All experiments were performed on
female Swiss albino mice weighing 25–30g and white New
Zealand rabbits, both male and female, weighing 1.5–2kg
[15] obtained from Central Animal Facility (CAF), SASTRA
University, Thanjavur. Animals were housed individually in
polypropylene cages (mice) and stainless steel cages (rabbits)
and kept in a room maintained at an average temperature
of 22◦C ± 3◦C and humidity 55.6%, with 12h darkness
(lights on from 06:30 to 18:30h) and fed with standard
pellet diet (Tetragon Pvt. Ltd, Bangalore, India) before a
week of start of experiment. The mice and the rabbits were
Table 1: Composition of rabbit diet.
Compositions Normal diet (%) HFD (%)
Moisture 7.36 3.24
Crude protein 16.45 22.15
Crude fat 2.89 24.72
Crude ﬁber 12.24 3.6
Calcium 1.26 1.16
Phosphorous 0.85 0.86
Total ash 6.79 6.83
allowed to have free access to food and tap water ad libitum.
From then on (t = 0) until the end of the experiment,
rabbits were fed a fat rich-chow (Table 1) obtained from
Tetragon Pvt. Ltd, Bangalore, India. The animals were kept
in cages with raised ﬂoors of wide wire mesh to prevent
coprophagy. All experiments were performed in accordance
with the protocol approved by the CAF and institutional
ethical committee (No: 27/SASTRA/IAEC/RPP), SASTRA
University, Thanjavur.
2.5. Acute Oral Toxicity Study. In an acute toxicity study,
using the up- and down-procedure, all fractions in peanut
oil (OECD 425; Accepted vehicle) were administered by oral
gavage to female Swiss albino mice. The mice were ∼6w e e k s
old and weighed from 25 to 30g. The general procedure
was as follows: one mouse was dosed at 175mgkg−1 body
weight (b.w.) and if no mortality or overt toxicity occurred
within 48h, another mouse was dosed at 550mgkg−1 b.w.
In the absence of toxicity, a third mouse was dosed at
2000mgkg−1 b.w., and, if again no evidence of toxicity
was observed, two additional mice were dosed at this level,
that is, 2000mgkg−1 b.w. [16]. In all cases, the dosing
volume is ﬁxed at 10mlkg−1 b . w .T h em i c ew e r eh o u s e d
individually in Polypropylene cages and were observed for
clinical signs of toxicity at 0–0.5, 0.5–1, 1-2, 2–4 and 48h
post dosing (with special attention during the ﬁrst 4h).
The body weights of each mice were recorded prior to test
articles administration and at 7 and 14 days post dosing.
Once daily, cage-side observations included changes in skin
fur, eyes and mucous membrane (nasal) and also respiratory
rate, circulatory (heart rate and blood pressure), autonomic
(salivation, lacrimation, perspiration, piloerection, urinary
incontinence and defecation) and central nervous system
(ptosis, drowsiness, gait, tremors and convulsion) changes.
The blood plasma was collected through retro orbital sinus
(1ml) for the hematological assessments. The mice were
sacriﬁced by high dose of Ketamine HCl, intravenous
(anestheticdose:22mgkg−1 intramuscular)on14dayspost-
dosing. The time of death, if any, was recorded. Necropsy
included a gross examination of all major organs. The study
was conducted in compliance with OECD Test Guideline 425
(Revised: 17 December 2001).
2.6.SelectionofDose. LD50 wasdoneasperOECDguidelines
for ﬁxing the dose for biological evaluation. The LD50 ofEvidence-Based Complementary and Alternative Medicine 3
ethanolic fraction of TA falls under class four values with no
signs of acute toxicity at 2000mgkg−1 in mice. For biological
evaluation in rabbits, the mice LD50 dose was converted into
rabbitdosebasedonthebodysurfaceareaandmetabolicrate
constant (FDA Guidelines, 2002). Hence, it was found that
926.66mgkg−1 andfromwhichthebiologicalevaluationwas
carried out at approximate doses of 100 and 200mgkg−1 in
rabbits.
2.7. Experimental Design. Preceding the study, all rabbits
consumed the same diet for one week. Twenty New Zealand
rabbits were randomly divided into ﬁve groups each con-
taining four animals of both sexes (1:1) and fed one of the
followingfor72days:normaldiet(shownabove,n=4);HFD
(n=4); HFD with standard drug Atorvastatin (1mgkg−1, n
= 4); HFD with EtOH fraction dose I (100mgkg−1, n=4);
HC with EtOH fraction dose II (200mgkg−1, n=4). The
rabbit were weighed every week. At the end of experiment,
all rabbits were deprived of food overnight and sacriﬁced
under lethal dose of sodium pentobarbital 100mgkg−1 b.w.
Conﬁrmed death by the absence of a heart-beat, using
thoracic auscultation. Blood was collected, and whole blood
and serum were prepared for laboratory analysis. The major
organs and aorta of each rabbit were harvested, washed with
ice-cold isotonic saline and weighed. The serum samples
were stored in refrigerator and aorta samples were stored in
deep freezer until analyzed.
2.8. Serum Lipid Proﬁle. Blood samples were taken from the
rabbits on baseline, 14th day, 36th day and 72nd day and
the serum was used to determine levels of total cholesterol
(TC), triglyceride (TG), low density lipoprotein cholesterol
(LDL-C), very low density lipoprotein cholesterol (VLDL-
C) and high density lipoprotein cholesterol (HDL-C). The
concentration of the above-said parameters is measured
using biochemical test kits with the semi auto analyzer by
colorimetric method.
2.9. Atherogenic Index. The atherogenic index serum (AIS)
which is the measure of the extent of atherosclerotic lesions
based on serum lipids is determined in all ﬁve groups. The
atherogenic index is calculated using the formula AIS =
TC/HDL [17].
2.10. Processing of Aorta Fragment. After the rabbits were
sacriﬁced, tissues between their origin and bifurcation into
the iliac arteries were taken gently, and washed with ice
cold sterile physiologic saline to remove debris and blood
residues. The proximal ascending aortic arch was dissected
from each rabbit and divided into three 3-mm cross sections.
These cross sections of aorta were cut open longitudinally
and the adventitial coat was removed and the tunia media
and tunia intima were stored in deep freezer (−80◦C) for
biochemical analyses [18].
2.11. Assessment of Atherosclerotic Plaques. Staining of a
paraﬃn section with Haematoxylin (Hx) and Eosin (E) was
done according to the Carleton method. The aorta was
removed from the formal saline and a block of hard paraﬃn
with the tissue in its center was prepared for sectioning. The
paraﬃn (wax around the organ) was dissolved by putting
the slide in xylol solution for 3min, and then the xylol
was replaced by alcohol by putting the slide in absolute
alcohol. The slide was hydrated by putting it in descending
grades of alcohol (in 100% alcohol, then in 90%, then in
70% alcohol and ﬁnally distilled water) for 3min in each
step. The section was stained in Hx for 7min. This basic
stain stains the nuclei and the basophilic structures of the
cytoplasm with a blue color. The slide was put in tap water
for 5min to blue the section since the nuclei appears darker
after tap water. The section was stained in E for 1min. Eosin
stains the acidophilic structures of the cytoplasm with red
color. The slide was then washed in distilled water for 3min.
Dehydration of the slide was done by putting it in ascending
grades of alcohol (for 1min in 70% alcohol, then, for 3min
in90%andforanother3minin100%alcohol).Theslidewas
put in xylol in order to clear it from alcohol and to allow it to
be miscible with Canada balsam. A drop of Canada balsam
is put on a clean cover and the slide was removed from xylol
with its face downwards and is put quickly on the cover. The
stained section is thus ready for microscopical examination.
2.12. Statistical Analysis. All data are expressed as mean
± SEM and the statistical signiﬁcance was performed by
repeated measures ANOVA with Turkey’s multiple compari-
son post hoc test. A P-value < .05 was considered signiﬁcant.
3. Results
3.1. Fractionation and Phytochemical Investigation. The
yields (Y) of the fractions TA-01, TA-02 and TA-03 were
found to be 0.42, 0.978 and 24.16%, respectively. The yield
of the ethanol fraction was much higher (i.e., 24.16%) than
the other fractions. Phytochemical analysis revealed that
TA fractions (TA-01, TA-02 and TA-03) contain phenolics,
tannins, triterpenoid, saponins, anthraquinone glycosides,
alkaloids and ﬂavonoids. The HPTLC ﬁngerprint combined
with phytochemical analysis strongly suggests that the peaks
observed correspond to phenolic compounds, tannins, gly-
cosides, saponins, alkaloids and ﬂavonoids [13, 19–21]. The
GC-MS studies concluded that the presence of plant sterols
is high in ethanolic fraction (Figure 1).
3.2. Acute Toxicity Studies. The acute oral toxicological study
has not shown any deviation from the normal behavior of
the Swiss albino mice during the entire study period. So,
there were no acute toxicological changes for the ethanolic
fraction of T. arjuna up to 2000mgkg−1 b.w. of the animals.
The biological evaluation was carried out at doses of 100 and
200mgkg−1 b.w. in rabbits.
3.3. Lipid Proﬁle. Total cholesterol concentrations of HFD
group (baseline 53.42 ± 3.66mgdl−1) were increased to
143.36 ± 8.01, 552.55 ± 42.00 and 868.43 ± 47.98mgdl−1
after 14, 36 and 72 days, respectively. At the same time,
Atorvastatin points out signiﬁcantly lowered levels of TC to4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: GC-MS analysis showing the presence of plant sterols.
49.91, 51.16 and 55.70% of those of the HFD (P < .05).
Similarly,asigniﬁcantreductioninthetotalcholesterollevels
was also evident in HFD with EtOH fraction of T. arjuna
bark. When treated with EtOH in 100mgkg−1 of dose, the
total cholesterol was reduced to the levels of 14.27, 27.61 and
30.36% of those of the HFD group (P < .05). Treated group
of EtOH fraction in 200mgkg−1, the TC level was found
to have of reduction to 24.16, 37.91 and 44.41% of those
of the HFD group (P < .05). Triglyceride concentrations of
HFD group (70.62 ± 4.11) were increased to 259.76 ± 28.49,
565.50 ± 33.55 and 784.36 ± 47.92 after 14, 36 and 72 days,
respectively. Atorvastatin signiﬁcantly lowered the levels of
TG to 57.1, 67.29 and 70.35% of those of the HFD (P < .05).
WhentreatedwithEtOHfractionin100mgkg−1 ofdose,the
TG reduced levels to 19.43, 22.29 and 29.62% of those of
the HFD group (P < .05). Treated group of EtOH fraction
in 200mgkg−1, the TG level was reduced to 35.36, 37.31
and 46.96% of those of the HFD group (P < .05). Changes
in the LDL-C and VLDL-C levels were paralleled to serum
cholesterol and triglycerides in all the treated groups and
signiﬁcant reduction in LDL-C and VLDL-C were found in
Atorvastatin and EtOH fraction 100 and 200mgkg−1 treated
groups (P < .05) (Table 2). The HDL increased signiﬁcantly
in the treated group when compared with HFD group (P <
.05) at 36 and 72 day of treatment. At 14th day treatment
groups had shown no signiﬁcant change in HDL level (P >
.05).
3.4. Serum Atherogenic Index. Serum atherogenic index
(28.94 ± 41.55) was high in HFD group after the 72 days of
analysis and the signiﬁcant reduction of atherogenic index
was present in treated groups when compared with the HFD
group (P < .05) (Figure 2).
3.5. Histopathological Findings. Histopathological examina-
tion of aorta obtained from the normal control group is
shown in Figure 3. The aorta wall shows a uniform thickness
with no bulging in the lumen and the endothelial lining
is intact without any interruption. Also, elastic lamina and
muscle ﬁbers appear normal. On the other hand, all rabbits
that received the 24% high fat-enriched diet for 72 days
developed atherosclerotic lesions that appeared as marked
alterations in the aortic wall, represented by the intimal
plaques indicated by arrows in Figure 4. Administration of
Atorvastatin in addition to a hypercholesterolaemic diet for
72 days completely improved the aortic architecture which
is severely disturbed by hypercholesterolaemia. The aortaEvidence-Based Complementary and Alternative Medicine 5
Table 2: Serum lipid proﬁle and atherogenic index.
No. of days Parameters Control D. Control Std EtOH 100 (mgkg−1) EtOH 200 (mgkg−1)
Baseline
TC (mgdl−1) 54.02 ± 1.99 53.42 ± 3.66 55.84 ± 3.44 54.91 ± 4.50 54.38 ± 3.04
HDL (mgdl−1) 31.69 ± 1.95 30.03 ± 1.15 29.47 ± 1.50 26.62 ± 1.88 30.62 ± 2.16
LDL (mgdl−1)7 . 5 0 ± 3.41 5.86 ± 3.89 10.93 ± 3.62 14.13 ± 4.54 9.64 ± 2.06
VLDL (mgdl−1) 14.83 ± 0.73 17.53 ± 0.48 15.44 ± 0.77 14.16 ± 0.66 14.12 ± 0.82
TG (mgdl−1) 74.15 ± 3.65 87.63 ± 2.42 77.18 ± 3.85 70.80 ± 3.31 70.62 ± 4.11
14 days
TC (mgdl−1) 63.63 ± 4.95 143.36 ± 8.01(a) 71.82 ± 5.30(b) 122.90 ± 8.18(a),(b),(c) 108.76 ± 6.67(b),(c),(d)
HDL (mgdl−1) 35.13 ± 1.98 34.75 ± 4.27 38.25 ± 4.35 38.44 ± 1.62 40.50 ± 2.65
LDL (mgdl−1)7 . 0 9 ± 7.09 15.86 ± 12.92 6.14 ± 5.68 15.73 ± 4.36 13.69 ± 9.78
VLDL (mgdl−1) 35.59 ± 1.66 92.75 ± 12.67(a) 39.70 ± 1.62(b) 68.73 ± 3.90(a),(b),(c) 51.95 ± 5.70(a),(b),(d)
TG (mgdl−1) 177.93 ± 8.29 463.77 ± 63.37(a) 198.50 ± 8.10(b) 373.63 ± 19.48(a),(b),(c) 299.76 ± 28.49(a),(b),(d)
36 days
TC (mgdl−1) 254.86 ± 2.18 552.55 ± 42.00(a) 269.83 ± 11.45(b) 399.96 ± 41.61(a),(b),(c) 359.65 ± 41.08(a),(b),(c)
HDL (mgdl−1) 33.94 ± 2.21 32.94 ± 3.56 38.00 ± 5.89 34.00 ± 4.40 37.91 ± 1.64
LDL (mgdl−1) 170.49 ± 5.41 347.48 ± 32.80(a) 175.53 ± 9.05(b) 177.33 ± 39.96(b) 208.64 ± 42.99(b)
VLDL (mgdl−1) 50.43 ± 6.57 172.13 ± 12.35(a) 56.29 ± 1.79(b) 138.63 ± 3.72(b) 113.10 ± 6.71(a),(b),(c),(d)
TG (mgdl−1) 252.15 ± 32.84 860.65 ± 61.77(a) 281.46 ± 8.96(b) 663.16 ± 18.58(a),(b),(c) 539.50 ± 33.55(a),(b),(c),(d)
72 days
TC (mgdl−1) 353.78 ± 5.78 868.43 ± 47.98(a) 384.69 ± 4.94(b) 604.58 ± 27.42(a),(b),(c) 543.47 ± 53.91(a),(b),(c),(d)
HDL (mgdl−1) 34.25 ± 1.71 30.00 ± 1.15 41.75 ± 4.92(b) 35.25 ± 2.99 38.58 ± 4.38(b)
LDL (mgdl−1) 252.41 ± 7.47 582.44 ± 52.37(a) 267.06 ± 2.23(b) 489.17 ± 33.85(a),(b),(c) 348.02 ± 63.85(a),(b),(d)
VLDL (mgdl−1) 67.11 ± 3.45 255.98 ± 7.82(a) 75.88 ± 2.25(b) 180.16 ± 13.48(a),(b),(c) 156.87 ± 9.58(a),(b),(c),(d)
TG (mgdl−1) 335.57 ± 17.27 1279.92 ± 39.09(a) 379.38 ± 11.23(b) 900.79 ± 67.40(a),(b),(c) 704.36 ± 47.92(a),(b),(c),(d)
Atherogenic Index 10.32 ± 2.38 28.94 ± 2.55 9.21 ± 1.02 19.98 ± 4.18 14.08 ± 3.31
Values expressed are mean ± SD of four animals per group.
(a),(b),(c),(d)statistical signiﬁcance at P < .05 when compared with control, disease control, standard and treatment, respectively, on performing repeated
measures ANOVA with Tukey’s multiple comparison post hoc test.
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Figure 2: Atherosclerotic index.
wall appears normal in Figure 5, with no foam cells, no
disturbance in the endothelial lining and no change in the
muscle ﬁbers. In animals fed on high fat diet supplemented
withEtOHfractionsandhighfatdietthetunicaintimaofthe
aorta is thickened but the atheromatous plaques are never
as high and wide as plaques seen in the aorta of rabbits
administeredsolelyhighfatdiet.Theyareincludedwithlipid
droplets,foamcellsandelasticﬁbers.Lowdosetreatedrabbit
aortic sections have indicated a moderate thickening of the
arterial wall in all the rabbits (Figure 6). High dose treated
rabbit aortic sections have revealed the presence of relatively
normal aortic wall (Figure 7).
4. Discussion
Natural products extracts of therapeutic relevance are of
paramount importance as reservoirs of structural and chem-
ical diversity [22]. Epidemiological studies have reported a
reduced risk of coronary heart disease in subjects with high
ﬂavonoid intake [23, 24] .T h ep r o t e c t i v ee ﬀect of ﬂavonoids
hasbeenattributedtomanymechanisms,thatis,antioxidant
properties, anti-inﬂammatory activity [25], antiproliferative
aswellasanti-plateleteﬀects[26,27].TheT. arjuna ethanolic
fraction contains ﬂavones and tannins [13, 28]. The GC-
MS studies found that the presence of plant sterols is high6 Evidence-Based Complementary and Alternative Medicine
Figure 3: Aortic section of the control group rabbit revealing no
pathological changes. HE × 5.
Figure 4: Thickening of the arterial wall in aortic section of the
diseased control group. HE × 10.
in ethanolic fraction. The tannins and ﬂavones may act
as in free radical scavenging mechanism and may prevent
atherogensis in rabbit aorta. While the plant sterols may
be interacted with the intestinal absorption of fats and
cholesterols, it will promote the fecal elimination of the fats
and cholesterols [29]. The therapeutic activities of T. arjuna
with the present study has been represented in a schematic
diagram (Figure 8).
Oneofthekeystepsinthedevelopmentofatherosclerosis
is oxidative modiﬁcation of LDL, which are scavenged by
macrophages leading to formation of foam cells in the vessel
wall, belonging to the early changes initiating the formation
of atherosclerotic plaque. Atherosclerotic index indicates
the deposition of foam cells or plaque or fatty inﬁltration
or lipids in heart, coronaries, aorta, liver and kidney. The
higher the atherosclerotic index the bigger the risk of these
organs for oxidative damage. The Atherosclerotic index was
signiﬁcantlyreducedinethanolicfractionofT. arjuna treated
hypercholesterolemic rabbits. BHUx-mediated reduction in
the calcium content in the atherosclerotic plaque could also
be attributed to its antioxidant property or to the calcium
channel blocking property of T. arjuna [9].
A case-controlled study in rabbits fed on high cholesterol
diet and administered T. arjuna bark powder 250mgkg−1
twicedailywascarriedoutrecentlytodetermineitshypolipi-
daemiceﬀect.ItwasfoundthattherabbitsreceivingT. arjuna
h a dam a r k e dr e d u c t i o ni nt o t a lc h o l e s t e r o l( P < .02) than
Figure 5: Presence of normal architecture of the aorta in the
standard drug treated group. HE × 10.
Figure 6: Low dose treated rabbit aortic section showing moderate
thickening of the arterial wall. HE × 10.
Figure 7: Aortic section of the high-dose group rabbit showing
relatively normal arterial wall. HE × 40.
control [27]. These ﬁndings are further conﬁrmed in a later
work [30–32].
In another experimental study this time using its ethano-
lic extract in doses of 100 and 500mgkg−1, a signiﬁ-
cant reduction in total and LDL cholesterol are noted in
hypercholesterolaemic rabbits. At 500mgkg−1 doses also,
a reduction is noted down in total: HDL and LDL:HDL
ratio. It is also found that fat deposition in heart, liver
and kidney is signiﬁcantly low in those who received the
drug. This has been related to our ﬁndings that the fat is
deposited in the liver and heart. The absolute liver weightEvidence-Based Complementary and Alternative Medicine 7
Figure 8: Schematic diagram.
is increased and HFD groups expressed as increased weight
and fatty liver. Signiﬁcantly, the extract has not adversely
aﬀected the biochemical tests of liver and renal functions,
and haematological parameters [33]. It relates our present
report, that there was no signiﬁcant change in hematological
parameters (P > .05) except WBC. In HFD group, WBC
count is increased signiﬁcantly (P < .05) and the treated
group shows the improvement in the WBC change (P <
.05). In the present study, HDL shows enhancement on
prolonged treatment of the EtOH fraction at high dose level
(200mgkg−1). Atorvastatin shows that signiﬁcant (P < .05)
enhancement in HDL at 14, 36 and 72 days of the study
period. Observation that HDL cholesterol has not changed
signiﬁcantly are at variance to that of earlier works [30–
32]. This result has been correlated to our study ﬁndings.
Fluctuation in the HDL levels needs to be sorted out. Among
three Terminalias, T. arjuna is observed to be the most
potent hypolipidaemic agent. Interestingly, it has also raised
high-density lipocholesterol. Besides hypolipidaemia, it has
also induced partial inhibition of aortic atherosclerosis, thus
showing anti-atherogenic properties [19]. T. arjuna is also
highly eﬀective in inhibiting cell proliferation and possesses
anti-tumor activity through the interaction between tran-
scription factors and target DNA sequences [34].
5. Conclusion
The present study suggests that the ethanolic fraction from
T. arjuna bark powder has signiﬁcant anti-atherogenic activ-
ity when administered to normal or hypercholesterolemic
rabbits. The cardioprotective and anti-atherogenic eﬀects of
ethanolic fraction of T. arjuna may be due to presence of
ﬂavonoids, tannins and plant sterols. To elucidate the precise
mechanism of action of speciﬁc biological moiety, further
processing of ethanolic fraction of T. arjuna is required.
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